An approved medicine for specific diagnoses
Imcivree Eligibility, Care and Access
Imcivree contains setmelanotide. The FDA approves it for certain people with acquired hypothalamic obesity, Bardet-Biedl syndrome, or specific genetic deficiencies. The diagnosis, age and product label determine which care questions matter. A clinician can assess whether the labeled use fits a particular person.
Read moreShow less
- It acts on a different receptor from GLP-1 medicines.
- The FDA label excludes general obesity from its approved uses.
- Coverage, dispensing and personal cost need to be checked for the exact prescription.
Sources reviewed
The approved uses
The current FDA label covers these three situations. It does not cover obesity from other causes, including general obesity. A person’s diagnosis and test results need clinical review.
Age 4 and older
Acquired hypothalamic obesity
Obesity linked to hypothalamic injury or dysfunction. The diagnosis and clinical context need assessment by the care team.
Age 2 and older
Bardet-Biedl syndrome
A clinical diagnosis of Bardet-Biedl syndrome. The label describes when genetic confirmation should be considered.
Age 2 and older
POMC, PCSK1 or LEPR deficiency
The label calls for genetic testing and interpretation of the actual variant in the person’s clinical context.
What the evidence answers
A randomized trial found greater BMI reduction with setmelanotide than placebo in people with acquired hypothalamic obesity. Other studies support the Bardet-Biedl and genetic deficiency uses. Each study enrolled its own population. The setmelanotide profile explains the evidence by diagnosis.
The published acquired hypothalamic obesity paper and FDA label describe different analysis populations. Read a reported result with its own source and denominator.
Read the acquired hypothalamic obesity trialWhat care involves
Imcivree is a prescription injection taken once daily. The starting dose and how it changes depend on the labeled diagnosis, age and tolerability. The care team should review the label’s warnings and arrange monitoring, including mood and skin checks. People with acquired hypothalamic obesity may need additional monitoring for adrenal problems and, when central diabetes insipidus is present, sodium imbalance.
Rhythm’s U.S. prescribing instructions name PANTHERx Rare Pharmacy for electronic prescriptions. Its optional Rhythm InTune start form includes information often requested for insurance approval. Ask the prescriber or pharmacy for the actual medicine charge, coverage, and any separate visit or testing cost.
Read Rhythm’s pharmacy and insurance instructionsQuestions to take to the care team
Confirm the diagnosis
Which records establish the cause of obesity, and how do the current label’s age and testing criteria apply?
Review monitoring
Which warnings and monitoring steps in the Imcivree label matter for this person’s health history?
Check the access route
Who prescribes and dispenses the exact medicine, what does the plan require, and what is the full personal cost?
This guide does not contain a verified provider, coverage or price comparison for Imcivree.
See a problem or outdated information? Tell us.